Lung cancer with venous thrombo-embolism: clinical characteristics

##plugins.themes.academic_pro.article.sidebar##

Published Jul 12, 2011
Download
pdf
Vol. 89 No. 7 (2011): Issue Jul 2011

##plugins.themes.academic_pro.article.main##

Hajer Racil
Ghaya Laaribi
Hela Cherif
Sana Cheikh Rouhou
Asma Zidi
Mohamed Lamine Megdiche
Abdellatif Chabbou

Abstract

Background: Lung cancer is the most common malignancy diagnosed in patients with venous thrombo-embolism (VTE).
Aim: To investigate clinical, biological, radiological features and survival of lung cancer patients with VTE.
Methods: Retrospective case-control study investigating biologic, clinical course and survival of 25 patients lung cancers with VTE (Group M) and 50 lung cancers without VTE (group T).
Results: The frequency of the VTE was 5.88% with 2.58% pulmonary embolism (PE). The mean age was 58 years ± 9.8 in group M and 57.9 years ± 9.6 in group T. No significant difference concerning medical or surgical history for both groups was found.
The dyspnea and chest pain were at equal frequency (63.6%). Regarding the clinical probability of the PE, it was no significant differences between the two groups. A rate of D-dimer > 0.7μg/l was more frequent among group M (75% vs 20%; p = 0.054). The most common histological type was nonsmall cell lung cancer (88%). A stage IV was significantly more frequent in group M (86.4% vs. 52.3%; p = 0.007). The mean period of survival in Group M was 10.6 ± 1.2 month and 20.2 + 1.8 month in group T; p = 0.38.
Conclusion: The VTE associated to lung cancer is under diagnosed. Prospective studies are needed to establish more adapted scores.

Keywords:

Pulmonary embolism, venous thrombo-embolism, lung cancer

##plugins.themes.academic_pro.article.details##

References

  1. Ma SQ, Lin Y, Ying HY, Shao YJ, Li XY, Bai CM. Solid malignancies complicated with pulmonary embolism: clinical analysis of 120 patients. Chin Med J 2010; 123: 29-23.
  2. Chuang YM, Yu CJ. Clinical characteristics and outcomes of lung cancer with pulmonary embolism. Oncology 2009; 77: 100-6.
  3. Descourt R, Righini M, Carrier M, Le Gal G. Place of cancer among the risk factors in venous thromboembolism. Pathol Biol (Paris) 2008; 56:178-83.
  4. Chew HK, Davies AM, Wun T, Harvey D, Zhou H, White RH. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost 2008; 6: 601-8.
  5. Hicks LK, Cheung MC, Ding K, et al. Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials. Cancer. 2009; 115: 5516-25.
  6. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2008; 113: 223-4.
  7. Lee JE, Kim HR, Lee SM et al. Clinical characteristics of pulmonary embolism with underlying malignancy. Korean J Intern Med. 2010;25:66-70
  8. Letai A, Kuter DJ. Cancer, coagulation, and anticoagulation. Oncologist 1999;4: 443-9.
  9. Depierre A. Cancers broncho-pulmonaires: Mise au point. France: Editions John Libbey Eurotext. 2006:185-7.
  10. Tesselaar ME, Osanto S. Risk of venous thromboembolism in lung cancer. Curr Opin Pulm Med 2007; 13: 362-7.
  11. Sanchez O, Planquette B, Meyer G. Update on acute pulmonary embolism. Eur Respir J 2009; 18: 137-47.
  12. Lee JW, Cha SI, Jung CY, et al. Clinical course of pulmonary embolism in lung cancer patients. Respiration 2009; 78: 42-8.
  13. Tapson VF. The role of smoking in coagulation and thromboembolism in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005; 2: 71-7.
  14. Ambrosetti M, Ferrarese M, Codecasa LR, et al. Incidence of venous thromboembolism in tuberculosis patients. Respiration 2006; 73: 396.
  15. Vaidyula VR, Criner GJ, Grabianowski C, Rao AK. Circulating tissue factor procoagulant activity is elevated in stable moderate to severe chronic obstructive pulmonary disease. Thromb Res 2009; 124: 259-61.
  16. Ghandi R, Razak F, Tso P, Davey JR, Mahomed NN. Metabolic syndrome and the incidence of symptomatic deep vein thrombosis following total knee arthroplasty. J Rheumatol 2009; 36: 2298-301.
  17. Heit JA, Leibson CL, Ashrani AA, Petterson TM, Bailey KR, Melton LJ. Is diabetes mellitus an independent risk factor for venous thromboembolism? Arterioscler Thromb Vasc Biol 2009; 29: 1399.
  18. Celi A, Marconi L, Villari L, Palla A. The diagnosis of pulmonary embolism. Monaldi Arch Chest Dis 2009; 71: 47-53.
  19. O'Connell CL, Boswell WD, Duddalwar V, et al. Unsespected pulmonary emboli in cancer patients: clinical correlates and relevance. J Clin Oncol. 2006; 24: 4928-32.
  20. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715-22.
  21. Khorana AA. The NCCN Clinical practice guidelines on venous thromboembolic disease: strategies for improving VTE prophylaxis in hospitalized cancer patients. Oncologist 2007; 12: 1361-70.
  22. Bergqvist D, Agnelli G, Cohen AT, et al; ENOXACAN II Investigators: Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl Med 2002; 346: 975-80.
  23. Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 2007; 110: 1723-9.
  24. Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost 2007; 5: 520-7.
  25. Pavic M, Debourdeau P, Aletti M, Farge-Bancel D, Rousset H. Maladie veineuse thromboembolique et cancer. Rev Méd Intern 2006; 27: 313-22.
  26. Shao L, Wang ZH, Zuo JY. Clinical analysis of 23 lung cancer patients accompanied by pulmonary embolism. Ai Zheng 2009; 28: 416-9.
  27. Righini M, Le Gal G, De Lucia S, et al. Clinical usefulness of Ddimer testing in cancer patients with suspected pulmonary embolism. Thromb Haemost 2006; 95:715-9.
  28. Miron MJ, Perrier A, Bounameaux H, et al. Contribution of noninvasive evaluation to the diagnosis of pulmonary embolism in hospitalized patients. Eur Respir J 1999; 13: 1365-70.
  29. Altiay G, Ciftci A, Demir M, et al. High plasma D-dimer level is associated with decreased survival in patients with lung cancer. Clin Oncol (R Coll Radiol) 2007; 19: 494-8.
  30. Simanek R, Vormittag R, Ay C, et al. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna cancer and Thrombosis Study (CATS). J Thromb haemost 2009; 8: 114-20.